Search trials – HealthDB

Активни:

Намерени 4,781 изпитвания Стр. 61 от 240

Recruiting Phase 2

A Phase 2 Trial to Investigate Efficacy and Safety of Vipoglanstat in Women With Endometriosis

Endometriosis

The main objective of the trial is to evaluate the efficacy of vipoglanstat on endometriosis-related non-menstrual pelvic pain (NMPP).

Начало: 15.10.2025 Край: 01.06.2027 Възраст: 18–44 г.

Bulgaria, Czechia, Hungary +4 Gesynta Pharma AB NCT07260669

Recruiting Phase 1

A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease

Alzheimer's Disease

The purpose of this study is to: * Evaluate the safety and tolerability of intrathecal (IT) ALN-5288 in patients with Alzheimer's Disease (AD) * Evaluate the pharmacodynamic (PD) and pharmacokinetic (PK) effects of ALN-5288 after dose administration

Начало: 15.10.2025 Край: 06.03.2030 Възраст: 40–80 г.

Canada, Netherlands, Spain +1 Alnylam Pharmaceuticals NCT07214727

Recruiting

CAPIVASERTIB REGULATORY POSTMARKETING SURVEILLANCE IN KOREA

Breast Cancer

To fulfil the post-approval commitment of MFDS to conduct post-marketing surveillance, this study is designed to assess the known safety profile, identify previously unsuspected adverse reactions and to evaluate the effectiveness of Capivasertib under conditions of routine daily medical practice in Korea.

Начало: 15.10.2025 Край: 30.12.2029 Възраст: от 19 г.

South Korea AstraZeneca NCT06927648

Recruiting Phase 3

A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder

Alcohol Use Disorder

The purpose of this study is to see if brenipatide when compared to a placebo works and is safe for participants with moderate-to-severe Alcohol Use Disorder (AUD). Participation in this study will last approximately 56 weeks.

Начало: 15.10.2025 Край: 01.04.2028 Възраст: 18–75 г.

Belgium, China, Germany +5 Eli Lilly and Company NCT07219966

Recruiting

Effects of Spinal vs General Anesthesia on Systemic Inflammation in PCNL

Anesthesia Techniques Percutaneous Nephrolithotomy Systemic Inflammation

This observational study aims to compare the effects of spinal and general anesthesia on perioperative systemic inflammatory response in patients undergoing percutaneous nephrolithotomy (PCNL). Systemic inflammatory indices derived from routine complete blood count parameters, including Systemic Immune-Inflammation Index (SII), Systemic Inflammation Response Index (SIRI), Aggregate Index of Systemic Inflammation (AISI), Neutrophil-to-Lymphocyte Ratio (NLR), and Red Cell Distribution Width (RDW), will be evaluated. Preoperative and postoperative laboratory values will be analyzed to determine whether the type of anesthesia influences systemic inflammatory markers and related clinical outcomes.

Начало: 15.10.2025 Край: 30.04.2026 Възраст: от 18 г.

Turkey (Türkiye) Elazıg Fethi Sekin Sehir Hastanesi NCT07326670

Recruiting

Patient Outcomes Following Kinematic and Functional Alignment in Robotic-Assisted Total Knee Arthroplasty With Randomized Insert Types

Knee Osteoarthritis Degenerative Joint Disease of the Knee

This study aims to evaluate patient outcomes following robotic-assisted total knee arthroplasty using the VELYS system. Patients undergoing surgery will receive either kinematic alignment or functional alignment as determined by the operating surgeon as part of routine clinical care. Within each surgical technique group, patients will be randomly assigned to receive different implant insert types (medial stabilised or cruciate retaining) using a REDCap-based randomisation process. Patient-reported outcome measures will be collected before surgery and at follow-up time points after surgery to assess clinical outcomes.

Начало: 14.10.2025 Край: 14.10.2027 Възраст: от 18 г.

Singapore Singapore General Hospital NCT07533188

Recruiting

Pain Disengagement Training (Open Pilot)

Chronic Musculoskeletal Pain

The investigators aim to conduct an open pilot trial to determine the initial feasibility of a self-directed writing-based intervention in individuals with chronic musculoskeletal pain and elevated pain catastrophizing. The investigators will assess the feasibility of recruitment, acceptability of the treatment, credibility and participant satisfaction, treatment adherence, and feasibility of assessments following pre-specified benchmarks.

Начало: 14.10.2025 Край: 30.06.2026 Възраст: от 18 г.

United States Massachusetts General Hospital NCT06870162

Recruiting

Neurocognitive Ankle Training for Instability to Optimize Neuromusculoskeletal Outcomes (NATION)

Chronic Ankle Instability

The purpose of this study is to examine the effectiveness of a novel ankle rehabilitation protocol on improving clinical and health outcomes in physically active individuals with chronic ankle instability (CAI). Our central hypothesis is NATION, a novel rehabilitation intervention that includes neurocognitive tasks, will improve overall health and function, and reduce lower extremity musculoskeletal injury in physically active individuals with CAI.

Начало: 13.10.2025 Край: 14.06.2027 Възраст: 18–44 г.

United States Womack Army Medical Center NCT06527287

Recruiting Phase 2

A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin

Diabetes Mellitus, Type 2

The purpose of this study is to see how well LY3938577 works and how safe it is compared to degludec in people with type 2 diabetes. Participation in the study will last about 26 weeks.

Начало: 13.10.2025 Край: 01.12.2026 Възраст: 18–70 г.

Argentina, United States Eli Lilly and Company NCT07215312

Recruiting Phase 2

A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type Angelman Syndrome (AS)

Angelman Syndrome

The main goal of the study is to evaluate the safety and efficacy of GTX-102 in participants with Angelman syndrome.

Начало: 13.10.2025 Край: 01.01.2030 Възраст: 1–64 г.

Argentina, Brazil, France +5 Ultragenyx Pharmaceutical Inc NCT07157254

Recruiting

Ultra-processed Food-reducing Intervention and Continuous Glucose Monitoring

Postprandial Glucose Glucose Levels Hyperglycemias

The goal of this trial is to investigate whether reduction in ultra-processed food intake through dietary counseling and education can improve postprandial glucose responses and glycemic variability compared with a usual diet in young, healthy Korean adults aged 20-30 years. The main questions it aims to answer are: \- Does reducing ultra-processed food intake, while maintaining total energy intake and usual lifestyle behaviors, improve postprandial glucose and lower glycemic variability in healthy adults without diabetes? Participants will: * Undergo the 10-day pre-intervention monitoring period, during which each participant will wear a continuous glucose monitoring (CGM) device and concurrently report their daily dietary intakes (all food and beverage consumption) and other lifestyle behaviors (sleep, smoking, physical activity) * After the 10-day pre-intervention monitoring period, participants will be randomized to either intervention or control group * Intervention group: Participants will visit the research site to receive dietitian-led one-on-one nutrition education and personalized dietary counseling targeting reduction of ultra-processed food intake. Personalized diet counseling will be provided by study dietitian based on participant's records of dietary intakes during the 10-day pre-intervention monitoring period. * Control group: Participants will receive dietitian-led nutrition education and personalized dietary counseling based on the national dietary guidelines. * After the intervention, participants will undergo the 10-day post-intervention monitoring period, during which participants will wear a new CGM device for an additional 10 days and continue daily reporting of dietary intakes (all food and beverage consumptions) and lifestyle behaviors (sleep, smoking, physical activity).

Начало: 11.10.2025 Край: 31.08.2026 Възраст: 20–39 г.

South Korea Korea University NCT07175701

Recruiting Phase 1/2

Phase I/II Study of PRL3-zumab in Neovascular Age-related Macular Degeneration (nAMD)

Neovascular Age Related Macular Degeneration

Study Design This is a Single-center, Phase I/II placebo-controlled study to assess the safety and efficacy of PRL3-zumab in patients with Neovascular Age-related Macular Degeneration (nAMD). PRL3-zumab will be administered Intravenously in 2-week interval for 3 doses. Normal saline (0.9% Sodium Chloride w/v) will be used in placebo treatment. The study will consist of 3 arms. Arm-1: PRL3-zumab 3mg/kg intravenously in 2 week interval followed by 20 weeks of monitoring (n=6) Arm-2: PRL3-zumab 6mg/kg intravenously in 2 week interval followed by 20 weeks of monitoring (n=6) Arm-3: Placebo (normal saline 0.9% sodium chloride w/v) intravenously in 2 week interval followed by 20 weeks of monitoring (n=3) Initial 3 arms will be conducted on patients who failed Standard-of-Care (SOC) therapy. Response assessment will be done at every 4 weeks from last dose of treatment till 24-week. Randomization: Randomization will be done in 2:2:1 manner on PRL3-zumab (group 1), 3mg/kg (n=6); PRL3-zumab (group 2), 6mg/kg (n=6); and placebo group (group 3) (n=3). Randomization can be achieved using random number table which will be prepared before the commencement of clinical trial. The allocation of participants will be done by Investigator and will be concealed from the participants. Blinding: Single blinding will be done for this trial in which all participants are unaware of their treatment assignment. No blinding will be done on Investigator. Primary Endpoints: 1. Safety: • Adverse Events: Frequency and severity of adverse events throughout the primary outcome assessment period. 2. RP2D: • This study will confirm RP2D established from NUH Phase I Clinical Trial in Cancer patients (MC/03/0616). 3. Efficacy: * Change From Baseline in Best Corrected Visual Acuity (BCVA) Measured by the ETDRS Letter Score. Change in BCVA letter gain of 0-4. * Change From Baseline in Central Subfield Retinal Thickness (CST). \[Assessment Time Frame: 4 weekly through 24 weeks\] Secondary endpoints: * Change in visual Acuity (Best Corrected Visual Acuity) of 5 or more letters. * Proportion of patients gaining ≥15, ≥10, ≥5, or ≥0 ETDRS letters in BCVA from baseline over time * Proportion of patients avoiding a loss of ≥15, ≥10, or ≥5 ETDRS letters in BCVA from baseline over time * Proportion of patients with absence of intraretinal fluid * Proportion of patients with absence of subretinal fluid \[Assessment Time Frame: 4 weekly through 24 weeks\] Criteria for additional Therapy: Once the treatment is stopped after the third dose, patients from all groups are eligible for additional therapy as open-label treatment if there is recurrence of disease activity, as defined by presence of any of the following criteria: 1. Decrease of ≥5 letters in BCVA compared with average BCVA value over the previous two scheduled visits, owing to nAMD disease activity (as determined by the investigator). 2. Increase of \>50 µm in OCT-measured CST compared with the average CST value over the previous two scheduled visits. 3. Recurrence of intra-retinal or sub-retinal fluid (if resolved previously) 4. New macular hemorrhage Patients in the placebo group will be given PRL3-zumab (6mg/kg) if they fulfil the criteria for additional therapy. Additional therapy will be continued in subsequent monitoring visit until the progression of disease, or end of the trial. If patients show clinical benefit from the treatment, additional doses could be given based on investigators' judgment. Criteria for progression of disease: 1. BCVA decreases by 15 letters or more from best recorded BCVA because of nAMD disease activity. 2. an increase in OCT central retinal thickness 150 µm or more from lowest recorded measurement after 2 consecutive additional therapy occurring 1 month apart.

Начало: 11.10.2025 Край: 07.07.2027 Възраст: от 18 г.

Singapore Intra-IMMUSG Pte Ltd NCT07547228

Recruiting

Collaborative Opportunities for Reducing Alcohol and Sexual Violence Together

Sexual Violence Behavior Change Military Training

The goal of this clinical trial is to test if a modified peer-based motivational intervention (the Military PAIRS; MPAIRS) is reasonable and practical for military contexts. The main questions it aims to answer are: * Does it works to reduce SV? * Does it works to reduce risky drinking? To test this, participants will answer questions about their SV history and risky drinking. Then they will be given MPAIRS. After 1 month, they will be asked about their SV history and risky drinking again.

Начало: 10.10.2025 Край: 01.04.2027 Възраст: 18–24 г.

United States State University of New York at Buffalo NCT07261722

Recruiting

Determinants of the Response to BTK Degraders (BTKd) in Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia BTK Degraders

The aim of the REBELLE cohort - bio-collection is to collect samples from patients with Chronic Lymphocytic Leukemia candidates or those exposed to BTK degraders to evaluate the mechanisms of resistance to these new molecules. To do this, an additional blood or bone marrow sample to those planned in the context of patient care or a residual lymph node biopsy sample will be collected after signing consent.

Начало: 09.10.2025 Край: 15.09.2039 Възраст: от 18 г.

France Nantes University Hospital NCT07099443

Recruiting Phase 1/2

A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration

Geographic Atrophy

This is a sequential Phase 1/2, two-part, multicenter study on safety, tolerability, and efficacy of one-time intravitreal SAR446597 for the treatment of participants with Geographic Atrophy (GA) secondary to Age-related Macular Degeneration (AMD). The core phase duration will be approximately 2 years for each participant. An Extended Follow-Up (EFU) phase of 3 years follows the core phase. The treatment is a one-time intravitreal injection of SAR446597 (or sham as applicable in Part II).

Начало: 09.10.2025 Край: 22.07.2032 Възраст: от 60 г. Treatment

Australia, United States Sanofi NCT07215234

Recruiting

Efficacy and Safety of Cold Atmospheric Plasma Combined With Endovascular Intervention for Diabetic Foot Ulcers With Lower Extremity Arterial Occlusion

Diabetic Foot Ulcers (DFU) Lower Extremity Arterial Occlusion

The goal of this clinical trial is to evaluate whether cold atmospheric plasma (CAP) combined with endovascular intervention can accelerate wound healing and improve safety outcomes in patients aged 18 to 80 years with diabetic foot ulcers (DFUs) complicated by lower extremity arterial occlusion. The main questions it aims to answer are: 1. Does CAP treatment lead to a greater reduction in ulcer area by Week 4 compared to placebo?; 2. Is CAP therapy safe and well-tolerated in patients with DFUs after successful infrapopliteal revascularisation?; Researchers will compare CAP treatment plus standard care to sham CAP (placebo) plus standard care to see if CAP improves wound healing more effectively and reduces adverse local symptoms. Participants will: 1. Receive either active CAP therapy or sham CAP therapy once daily for 10 days following endovascular revascularisation 2. Undergo daily wound assessments for ulcer area, signs of infection, and pain scores 3. Complete quality-of-life questionnaires (EQ-5D and SF-12) at baseline and Week 4 4. Be followed through Week 4 to assess efficacy and safety endpoints

Начало: 09.10.2025 Край: 30.12.2026 Възраст: 18–80 г.

China Shenyang Medical College NCT07198061

Recruiting Phase 3

A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine

Mania Bipolar Disorder

The purpose of this study is to evaluate the efficacy and safety of adjunctive KarXT for the treatment of mania in participants with Bipolar-I Disorder.

Начало: 08.10.2025 Край: 28.06.2027 Възраст: 18–65 г.

Argentina, Bulgaria, China +10 Bristol-Myers Squibb NCT07140913

Recruiting Phase 3

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

Non-small Cell Lung Cancer

Researchers want to learn if the study medicines calderasib and subcutaneous (SC) pembrolizumab can be used to treat non-small cell lung cancer (NSCLC) when given together. Calderasib is a targeted therapy for the KRAS G12C mutation. The goal of this study is to learn if people who receive calderasib with SC pembrolizumab live longer without the cancer growing or spreading than in people who receive SC pembrolizumab with chemotherapy.

Начало: 08.10.2025 Край: 06.08.2032 Възраст: от 18 г. Treatment

Argentina, Australia, Austria +18 Merck Sharp & Dohme LLC NCT07190248

Recruiting Phase 2

A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)

Arthritis, Rheumatoid

Researchers are looking for new ways to treat rheumatoid arthritis (RA). Methotrexate (MTX) is a standard (usual) treatment for RA. However, MTX and other current treatments may not work well to treat RA symptoms for many people. This study will help find out if a study medicine called tulisokibart can treat symptoms of active RA in people who are taking MTX. In this study, researchers will look at different doses of tulisokibart. Researchers want to learn if at least one of the study doses of tulisokibart works better than a placebo to lessen RA symptoms. A placebo looks like the study medicine but has no study medicine in it. Using a placebo helps researchers better understand the effects of the study medicine.

Начало: 08.10.2025 Край: 03.09.2029 Възраст: 18–80 г.

Canada, Chile, China +8 Merck Sharp & Dohme LLC NCT07176390

Recruiting Phase 3

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis

This is a multinational, multicenter, randomized, double-blind, placebo-controlled, Phase 3 induction study to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active Ulcerative Colitis (UC). Study details include: The study duration may be up to 35 weeks with: * Screening period * 12-week Sub-Study 1 (Single-Arm Open-Label Feeder Induction) or Sub-Study 2 (Pivotal Induction) * 12-week Sub-Study 3 (Extended Induction for non-responders) * 45 days follow-up visit for participants who do not enroll into the maintenance study (EFC18359) The treatment duration will be up to 12 weeks in each sub-study. The number of scheduled on-site visits will be up to 8 for the Sub-Study 1 and Sub Study 2 or a maximum of 15 visits for participants completing extended induction.

Начало: 08.10.2025 Край: 09.05.2028 Възраст: 16–80 г.

Bulgaria, Canada, China +17 Sanofi NCT07184996

1 … 59 60 61 62 63 … 240